Table 2 Demographic characteristics of 371 participants
| Â | Herbal remedy use | Â | |
|---|---|---|---|
| Â | No (n = 154) | Yes (n = 217) | P valuea |
Ethnicity | Â | Â | 0.28 |
   White | 136 (40.6%) | 199 (59.4%) |  |
   Hispanic/Latino | 18 (50.0%) | 18 (50.0%) |  |
Age at diagnosis, years | Â | Â | 0.40 |
   < 35 | 37 (35.9%) | 66 (64.1%) |  |
   35-38 | 69 (43.4%) | 90 (56.6%) |  |
   39-40 | 48 (44.0%) | 61 (56.0%) |  |
Stage of cancer at diagnosis | Â | Â | 0.14 |
   In situ | 22 (43.1%) | 29 (56.9%) |  |
   Invasive local | 94 (45.2%) | 114 (54.8%) |  |
   Invasive non-local | 38 (33.9%) | 74 (66.1%) |  |
Type of no-surgical treatment | Â | Â | Â |
   No treatment | 40 (45.5%) | 48 (54.5%) | 0.83 |
   Chemotherapy only | 26 (41.9%) | 36 (58.1%) |  |
   Radiation therapy only | 26 (44.1%) | 33 (55.9%) |  |
   Hormonal therapy only | 5 (35.7%) | 9 (64.3%) |  |
   Any combination of therapies | 57 (38.5%) | 91 (61.5%) |  |
Type of surgery | Â | Â | 0.07 |
   Lumpectomy | 39 (34.5%) | 74 (65.5%) |  |
   Mastectomy | 115 (44.6%) | 143 (55.4%) |  |
Post-diagnosis cancer-related conditionsb | Â | Â | 0.26 |
   None | 98 (44.1%) | 124 (55.9%) |  |
   1 cancer condition | 35 (34.7%) | 66 (65.3%) |  |
   ≥ 2 cancer conditions | 21 (43.8%) | 27 (56.2%) |  |
Comorbiditiesc | Â | Â | Â |
   None | 39 (62.9%) | 23 (37.1%) | 0.0005 |
   1 medication | 47 (40.9%) | 68 (59.1%) |  |
   ≥ 2 medications | 68 (35.1%) | 126 (64.9%) |  |
Interval between diagnosis and baseline interview, years | Â | Â | 0.62 |
   10-11 | 42 (37.8%) | 69 (62.2%) |  |
   12-13 | 55 (42.3%) | 75 (57.7%) |  |
   ≥ 14 | 57 (43.9%) | 73 (56.1%) |  |
Yearly income at baseline | Â | Â | 0.02 |
   ≤ $30,000 | 18 (41.9%) | 25 (58.1%) |  |
   $30,001-$60,000 | 39 (38.2%) | 63 (61.8%) |  |
   $60,001-$100,000 | 32 (32.0%) | 68 (68.0%) |  |
   > $100,000 | 65 (51.6%) | 61 (48.4%) |  |